CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., MD Anderson, and Pfizer Inc. to develop Probody therapeutics. It also has a strategic collaboration with Amgen, Inc. to develop T cell-bispecific probody therapeutic targeting epidermal growth factor receptor-CD3. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
Phone650-515-3185
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$59.50 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions
What is CytomX Therapeutics' stock symbol?
CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."
How were CytomX Therapeutics' earnings last quarter?
CytomX Therapeutics Inc (NASDAQ:CTMX) posted its earnings results on Wednesday, August, 8th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.01. The biotechnology company earned $21.34 million during the quarter, compared to analyst estimates of $16.48 million. CytomX Therapeutics had a negative net margin of 142.19% and a negative return on equity of 89.22%. View CytomX Therapeutics' Earnings History.
When is CytomX Therapeutics' next earnings date?
What price target have analysts set for CTMX?
8 equities research analysts have issued 1-year price targets for CytomX Therapeutics' stock. Their forecasts range from $13.24 to $40.00. On average, they anticipate CytomX Therapeutics' share price to reach $23.6057 in the next twelve months. This suggests a possible upside of 119.2% from the stock's current price. View Analyst Price Targets for CytomX Therapeutics.
What is the consensus analysts' recommendation for CytomX Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytomX Therapeutics.
What are Wall Street analysts saying about CytomX Therapeutics stock?
Here are some recent quotes from research analysts about CytomX Therapeutics stock:
- 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (3/5/2019)
- 2. HC Wainwright analysts commented, "We have valued CytomX Therapeutics based on a discounted cash flow (DCF) assessment that is driven by a combination of CX-072 future sales and BMS-986249 future royalties on net sales." (9/13/2018)
Has CytomX Therapeutics been receiving favorable news coverage?
News articles about CTMX stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. CytomX Therapeutics earned a coverage optimism score of 1.1 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of CytomX Therapeutics' key competitors?
Some companies that are related to CytomX Therapeutics include Select Medical (SEM), Nabriva Therapeutics (NBRV), Udg Healthcare (UDHCF), Endo International (ENDP), NeoGenomics (NEO), InVitae (NVTA), Heron Therapeutics (HRTX), Mallinckrodt (MNK), Arrowhead Pharmaceuticals (ARWR), Atara Biotherapeutics (ATRA), Allscripts Healthcare Solutions (MDRX), Xencor (XNCR), Hexo (HEXO), Rhoen Klinikum (RHK) and Healius (HLS).
What other stocks do shareholders of CytomX Therapeutics own?
Who are CytomX Therapeutics' key executives?
CytomX Therapeutics' management team includes the folowing people:
- Dr. Sean A. McCarthy, Chairman, CEO & Pres (Age 52)
- Mr. Debanjan Ray, CFO & Head of Corp. Devel. (Age 41)
- Dr. Rachel Wallach Humphrey, Chief Medical Officer (Age 58)
- Dr. Hoyoung Huh, Special Advisor to Chief Exec. Officer (Age 50)
- Dr. W. Michael Kavanaugh, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 63)
Who are CytomX Therapeutics' major shareholders?
CytomX Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (13.16%), BlackRock Inc. (8.58%), Perceptive Advisors LLC (6.47%), Victory Capital Management Inc. (2.04%), RTW Investments LP (2.02%) and Geode Capital Management LLC (1.26%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Frederick W Gluck, Kevin P Starr, Lloyd A Rowland, Rachel Humphrey, Robert C Goeltz II, Robert I Tepper, Rock Ventures Lp Third, Sean A Mccarthy and William Michael Kavanaugh. View Institutional Ownership Trends for CytomX Therapeutics.
Which institutional investors are selling CytomX Therapeutics stock?
CTMX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, Two Sigma Investments LP, Barclays PLC, Hamilton Lane Advisors LLC, Two Sigma Advisers LP, MetLife Investment Advisors LLC and Squarepoint Ops LLC. Company insiders that have sold CytomX Therapeutics company stock in the last year include Debanjan Ray, Frederick W Gluck and Sean A Mccarthy. View Insider Buying and Selling for CytomX Therapeutics.
Which institutional investors are buying CytomX Therapeutics stock?
CTMX stock was acquired by a variety of institutional investors in the last quarter, including RTW Investments LP, Perceptive Advisors LLC, Artal Group S.A., Candriam Luxembourg S.C.A., Citigroup Inc., United Services Automobile Association, Geode Capital Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for CytomX Therapeutics.
How do I buy shares of CytomX Therapeutics?
Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CytomX Therapeutics' stock price today?
One share of CTMX stock can currently be purchased for approximately $10.77.
How big of a company is CytomX Therapeutics?
CytomX Therapeutics has a market capitalization of $485.85 million and generates $59.50 million in revenue each year. The biotechnology company earns $-84,600,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis.
What is CytomX Therapeutics' official website?
How can I contact CytomX Therapeutics?
CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]
MarketBeat Community Rating for CytomX Therapeutics (NASDAQ CTMX)
MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe CTMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
